Twist Bioscience Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TWST research report →
Range $89 – $215
Price Chart
About the company
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage.
- CEO
- Emily Marine Leproust
- IPO
- 2018
- Employees
- 979
- HQ
- South San Francisco, CA, US
AI snapshot
Six angles, distilled from the data.
The stock is still in a long-term recovery phase, holding above its 200-day average after a sharp multi-month run, but it remains far below its 52-week high. That leaves the setup constructive yet volatile, with the recent pullback showing the trend can still reset quickly.
Street sentiment stays constructive, with a Buy consensus and an average target of 144.91 versus a 102.64 close. Recent calls have been mixed but still mostly supportive, with several firms trimming targets while keeping Buy or Hold views and only one fresh Sell initiation in the recent cluster.
The latest quarter beat by 25.6%, extending a 5-of-8 beat record, but the business still posts negative EPS and losses. Shareholders should watch whether revenue growth and margin discipline can keep improving while the next-year EPS estimate remains slightly negative at -0.4.
Recent insider activity leans to net selling, but much of the table reflects award-related grants rather than pure discretionary trades. The meaningful signal is that multiple officers and the CEO sold shares in November, which keeps sentiment cautious even as compensation-related awards were also booked.
Revenue growth is solid at 27.9% year over year, but profitability remains weak with a -28.79% operating margin and -28.34% net margin. The balance sheet is the offset: $581.9 million in cash against $95.0 million of debt leaves $486.9 million of net cash.
Twist stands out for growth and cash strength, but it still trails profitable biotech peers on margins and earnings power. At roughly 46x negative EPS, the valuation is still anchored more to future execution than current fundamentals.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.04B
- P/E
- -53.85
- Fwd P/E
- 97.93
- PEG
- 0.81
- P/S
- 16.05
- P/B
- 7.90
- EV/EBITDA
- -53.42
- Div Yield
- 0.00%
- Gross Margin
- 52.41%
- Op Margin
- -30.35%
- Net Margin
- -28.34%
- ROE
- -23.20%
- ROIC
- -13.84%
Latest fiscal year · YoY change
- Revenue
- $459.43M+22.0%
- Gross Profit
- $240.80M+26.1%
- Op Income
- $-139,455,000
- Net Income
- $-130,202,000-67.6%
- EPS
- $-2.08-60.0%
- OCF Growth
- +13.0%
- FCF Growth
- -17.7%
- 52W High
- $219.71
- 52W Low
- $25.67
- 50D MA
- $149.02
- 200D MA
- $94.55
- Beta
- 2.22
- RSI (14)
- 37
- Avg Volume
- 2.46M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Twist Bioscience posted 28% fourth-quarter revenue growth, delivered positive adjusted EBITDA in Q4, and guided FY2027 to more than 20% revenue growth with continued AI, NGS, and capacity expansion.· November 12, 2026
- Q4 revenue was $126.6 million, up 28% year over year, and full-year revenue was $459.4 million, up 22%.
- Gross margin improved to 53.1% in Q4 from 51.3% a year ago, and full-year gross margin was 52.4% versus 50.7%.
- Adjusted EBITDA turned positive in Q4 at $2.2 million, while full-year adjusted EBITDA was a loss of $35.9 million.
- AI drug discovery was a standout, with fiscal 2026 revenue of $59.1 million, up 175%, and management said orders could grow triple digits again in FY2027.
- Management guided FY2027 revenue to $550 million to $560 million and Q1 revenue to $130 million to $132 million, with gross margin around 52.5% to 53% and full-year adjusted EBITDA positive.
Fourth-quarter revenue was $126.6 million, up 28% year over year from $99 million, and up 7% sequentially. Full-year revenue was $459.4 million versus $376.6 million in fiscal 2025, up 22%. Fourth-quarter gross margin was 53.1% versus 51.3% a year ago; full-year gross margin was 52.4% versus 50.7%. Fourth-quarter adjusted EBITDA was positive $2.2 million; full-year adjusted EBITDA was a loss of $35.9 million. FY2027 guidance calls for revenue of $550 million to $560 million, about 21% growth at the midpoint, gross margin of approximately 52.5% to 53%, positive adjusted EBITDA, and capital expenditures of approximately $75 million, excluding landlord-funded tenant improvements. For Q1 FY2027, management expects revenue of $130 million to $132 million, about 26% year-over-year growth at the midpoint.
Emily Leproust framed FY2026 as a pivotal year, emphasizing that Twist accelerated top-line growth, achieved positive adjusted EBITDA in Q4, and expanded its capabilities for AI drug discovery, NGS, and therapeutics. Her tone was upbeat and confident, with repeated references to Twist’s structural advantages in customized manufacturing at scale and to the company’s ability to reinvest after crossing breakeven. She said the company is still early in AI drug discovery, sees significant upside beyond the current guide, and believes Twist has the platform, people, and capital to sustain growth.
Adam Laponis highlighted the core financial results: Q4 revenue of $126.6 million, full-year revenue of $459.4 million, Q4 gross margin of 53.1%, full-year gross margin of 52.4%, and Q4 adjusted EBITDA of $2.2 million. He also cited $582 million in cash, cash equivalents, and short-term investments at year-end, including $424.8 million from the public offering and ATM program, as well as $48 million of capex in FY2026 and about $75 million planned for FY2027. He said the company expects the planned investment program to support more than $1 billion in annual revenue within existing facilities and that the margin profile in FY2027 will reflect depreciation and manufacturing costs from bringing new capacity online ahead of utilization.
Analysts focused heavily on why FY2027 AI revenue guidance of $100 million does not appear to fully reflect the earlier triple-digit order-growth commentary. Management said the guide reflects only programs it can forecast with high confidence today, but it sees meaningful upside if it adds capacity and launches more workflows; Emily Leproust reiterated that triple-digit order growth is still expected and that the company intends to report only AI revenue it can clearly categorize. Questions also centered on the breadth of AI customers, the durability of AI demand, and the bridge from revenue growth to gross margin, where Adam Laponis said the business still has a path to 60% gross margin over time, though FY2027 will carry a 2 to 3 point gross margin headwind from depreciation on new capacity.
The call presented several visible growth engines: AI drug discovery revenue grew 175% in FY2026, NGS returned to above-20% growth, and management said it expects both AI and the broader business to keep growing in FY2027. Twist also ended the year with a strong cash position and positive Q4 adjusted EBITDA, giving it flexibility to invest ahead of demand. Management repeatedly stressed that customer demand is broadening, workflows are expanding, and the company has room to convert more of that demand into revenue.
The main risk is timing: management’s FY2027 revenue guide is based on programs it can forecast with high confidence, which means some of the perceived AI upside is not yet in the numbers. Gross margin expansion is expected to slow in FY2027 because capacity is being added ahead of utilization, creating a depreciation headwind. There is also some concentration and classification uncertainty in AI revenue, since management said it is becoming harder to separate AI from traditional drug-discovery activity and is only counting revenue it can clearly identify.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.2%
- Shares Outstanding
- 65.83M
- Float Shares
- 64.01M
of shares held by institutions
348 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for TWST, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Dwight EvansHouse · PA03 | Buy | Mar 2, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 9.70M | ▲ 4.99M |
| Blackrock, Inc. | 6.39M | ▲ 552.23K |
| Price T Rowe Associates Inc | 6.08M | ▲ 2.45M |
| Vanguard Group Inc | 5.78M | ▲ 8.05K |
| Ark Investment Management LLC | 3.40M | ▼ 1.15M |
| Vanguard Portfolio Management LLC | 3.12M | ▲ 297.46K |
| State Street Corp | 3.02M | ▼ 215.46K |
| Vanguard Capital Management LLC | 2.98M | ▲ 278.03K |
| Farallon Capital Management, L.L.C. | 2.14M | 0 |
| Artisan Partners Limited Partnership | 2.04M | ▼ 2.76M |
| D. E. Shaw & Co., Inc. | 1.83M | ▲ 640.75K |
| Invesco Ltd. | 1.82M | ▼ 106.34K |
Held by 523 ETFs
Biggest fund positions in TWST by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Cho Dennis | other | 7,045 |
| Nov 16, 26 | Cho Dennis | sell | 5,427 |
| Nov 16, 26 | Finn Patrick John | other | 18,206 |
| Nov 16, 26 | Finn Patrick John | sell | 12,752 |
| Nov 16, 26 | Green Paula | other | 6,372 |
| Nov 16, 26 | Green Paula | sell | 4,281 |
| Nov 16, 26 | Leproust Emily M. | other | 36,413 |
| Nov 16, 26 | Leproust Emily M. | sell | 19,045 |
| Nov 16, 26 | WERNER ROBERT F. | other | 3,641 |
| Nov 16, 26 | WERNER ROBERT F. | sell | 1,637 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TWST coverage
Recent articles, reports, and earnings notes.

Twist Bioscience (TWST): AI Discovery and Margin Leverage
Twist Bioscience is posting strong revenue growth and improving margins, but valuation remains demanding. The stock earns a Hold as the company works toward adjusted EBITDA breakeven in fiscal Q4 2026.

Imperium, Revealed: What Stock Is Adam O’Dell Teasing in Green Zone Fortunes?
Adam O’Dell and Money & Markets are pushing Imperium, the Green Zone Fortunes pitch built around the DNA revolution. We identify the company behind it and test the claims.

Twist Bioscience Corporation (TWST) drops on deep earnings beat
Twist Bioscience Corporation (TWST) beat earnings and revenue estimates, yet the stock drops as investors weigh valuation, margin progress and growth expectations. This deep-dive examines the company’s 15th straight quarter of sequential revenue growth, AI drug discovery momentum, NGS expansion and the path toward sustained profitability.
Want a deeper read on TWST?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Artisan Global Discovery Fund Q3 2026 Portfolio Activity
seekingalpha.com · Nov 18
Twist Bioscience: Long-Term 'Buy' On AI Discovery For Biotech
seekingalpha.com · Nov 16
Cathie Wood Is Buying the CoreWeave Dip and Selling Palantir
247wallst.com · Nov 13
Twist Bioscience Q4 Earnings Call Highlights
marketbeat.com · Nov 12
Twist Bioscience: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 12
Twist Bioscience Corporation (TWST) Q4 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Alger Mid Cap 40 ETF Q3 2026 Portfolio Review
seekingalpha.com · Nov 12
Twist Bioscience (TWST) Reports Q4 Loss, Beats Revenue Estimates
zacks.com · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice